ArticleBioinformatics (Oxford, England)2025
adverSCarial: assessing the vulnerability of single-cell RNA-sequencing classifiers to adversarial attacks.
Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
motivationSeveral machine learning (ML) algorithms dedicated to the detection of healthy and diseased cell types from single-cell RNA sequencing (scRNA-seq) data have been proposed for biomedical purposes. This raises concerns about their vulnerability to adversarial attacks, exploiting threats causing malicious alterations of the classifiers' output with defective and well-crafted input.
resultsWith adverSCarial, adversarial attacks of single-cell transcriptomic data can easily be simulated in a range of ways, from expanded but undetectable modifications to aggressive and targeted ones, enabling vulnerability assessment of scRNA-seq classifiers to variations of gene expression, whether technical, biological, or intentional. We exemplify the usefulness and performance with a panel of attack modes proposed in adverSCarial by assessing the robustness of five scRNA-seq classifiers, each belonging to a distinct class of ML algorithm, and explore the potential unlocked by exposing their inner workings and sensitivities on four different datasets. These analyses can guide the development of more reliable models, with improved interpretability, usable in biomedical research and future clinical applications. AVAILABILITY AND IMPLEMENTATION: adverSCarial is a freely available R package accessible from Bioconductor: https://bioconductor.org/packages/adverSCarial/ or https://doi.org/10.18129/B9.bioc.adverSCarial. A development version is available at https://github.com/GhislainFievet/adverSCarial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.